{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:38:32Z","timestamp":1648741112273},"reference-count":3,"publisher":"Hogrefe Publishing Group","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Praxis"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p> Zusammenfassung. Die Polycythaemia vera geh\u00f6rt zu den chronisch myeloproliferativen Neoplasien, die mit einer gesteigerten Proliferation aller drei Zellreihen (Erythro-, Granulo- und Megakaryopoiese) einhergeht. Bei fast allen Patienten liegt urs\u00e4chlich daf\u00fcr eine aktivierende Mutation im JAK2-Tyrosinkinase-Gen vor. Im Rahmen der Erythrozytose kann es zu Symptomen kommen, die durch die erh\u00f6hte Blutviskosit\u00e4t bestimmt sind. Weitere Symptome sind ein aquagener Pruritus und die Erythromelalgie. Die h\u00e4ufigsten Komplikationen sind thromboembolische Ereignisse. Risikofaktoren daf\u00fcr sind ein h\u00f6heres Lebensalter (&gt;60 Jahre) und eine bereits stattgehabte Thrombose. Als prim\u00e4re Therapie wird neben Aderl\u00e4ssen niedrigdosierte Acetylsalicyls\u00e4ure 100 mg t\u00e4glich verwendet. Ziel der Therapie ist es, thromboembolische Ereignisse zu verhindern. Im Verlauf ben\u00f6tigen die meisten Patienten daf\u00fcr eine zytoreduktive Therapie. <\/jats:p>","DOI":"10.1024\/1661-8157\/a003317","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T09:19:01Z","timestamp":1569921541000},"page":"835-842","source":"Crossref","is-referenced-by-count":0,"title":["CME: Polycythaemia vera"],"prefix":"10.1024","volume":"108","author":[{"given":"Mirjam","family":"Wellauer Atencio","sequence":"first","affiliation":[{"name":"Akutgeriatrie, Kantonsspital Winterthur"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen S.","family":"Goede","sequence":"additional","affiliation":[{"name":"H\u00e4matologie, Kantonsspital Winterthur"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","reference":[{"key":"c1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-579136"},{"key":"c2","unstructured":"Lengfelder E,                                 Baerlocher GM,                                 D\u00f6hner K,                                 Gisslinger H,                                 Griesshammer M,                                 Koschmieder S,                                 Petrides PE:                         Polycythemia vera. https:\/\/www.onkopedia.com\/de; letzter Zugriff: April                     2019."},{"key":"c3","first-page":"796","volume-title":"Differenzialdiagnose Innerer Krankheiten","volume":"21","author":"Goede JS"}],"container-title":["Praxis"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/1661-8157\/a003317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T04:24:48Z","timestamp":1615955088000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/1661-8157\/a003317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":3,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1024\/1661-8157\/a003317"],"URL":"https:\/\/doi.org\/10.1024\/1661-8157\/a003317","relation":{},"ISSN":["1661-8157","1661-8165"],"issn-type":[{"value":"1661-8157","type":"print"},{"value":"1661-8165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}